213 related articles for article (PubMed ID: 35472699)
1. Use of immunotherapy in clinical management of genitourinary cancers - a review.
Mar N; Uchio E; Kalebasty AR
Cancer Treat Res Commun; 2022; 31():100564. PubMed ID: 35472699
[TBL] [Abstract][Full Text] [Related]
2. Landscape of Immunotherapy in Genitourinary Malignancies.
Ravindranathan D; Alhalabi O; Rafei H; Shah AY; Bilen MA
Adv Exp Med Biol; 2021; 1342():143-192. PubMed ID: 34972965
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution.
Lu K; Chiu KY; Cheng CL
Cancer Treat Res; 2022; 183():201-223. PubMed ID: 35551661
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for genitourinary tumors.
Nakayama T; Kitano S
Int J Urol; 2019 Mar; 26(3):326-333. PubMed ID: 30710374
[TBL] [Abstract][Full Text] [Related]
5. Optimal Selection of Patients with Genitourinary Cancers for Anti-PD1/PD-L1 Treatment with a Focus on Urothelial and Renal Cell Carcinoma.
Zeuschner P; Junker K
Eur Urol Focus; 2022 Jul; 8(4):907-909. PubMed ID: 35918269
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review.
Kato M; Uchida J
Int J Urol; 2023 Dec; 30(12):1068-1077. PubMed ID: 37602512
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
8. Immuno-Oncology Advances in Genitourinary Cancers.
Zang PD; Angeles A; Dorff TB; Pal SK; Gupta S
Am Soc Clin Oncol Educ Book; 2024 Jan; 44(2):e430428. PubMed ID: 38206274
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Genitourinary Cancers: Role of Surgical Pathologist for Detection of Immunooncologic Predictive Factors.
Bahlinger V; Hartmann A; Eckstein M
Adv Anat Pathol; 2023 May; 30(3):203-210. PubMed ID: 36730368
[TBL] [Abstract][Full Text] [Related]
10. Combination of radiation and immunotherapy in the treatment of genitourinary malignancies: A systematic review and meta-analysis.
Maisch P; Koll F; Bolenz C; Chun FK; Gschwend JE; Schmid SC
Urol Oncol; 2023 May; 41(5):219-232. PubMed ID: 36372634
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.
Surolia I; Gulley J; Madan RA
Expert Opin Biol Ther; 2014 Dec; 14(12):1769-81. PubMed ID: 25212872
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in genitourinary malignancies.
Wattenberg MM; Fong L; Madan RA; Gulley JL
Curr Opin Urol; 2016 Nov; 26(6):501-7. PubMed ID: 27471994
[TBL] [Abstract][Full Text] [Related]
13. Current Landscape of Immunotherapy in Genitourinary Malignancies.
Alhalabi O; Rafei H; Bilen MA; Shah AY
Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013
[TBL] [Abstract][Full Text] [Related]
14. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
15. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
Hwang I; Park I; Yoon SK; Lee JL
Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
[TBL] [Abstract][Full Text] [Related]
16. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibition in upper tract urothelial carcinoma.
Califano G; Ouzaid I; Verze P; Hermieu JF; Mirone V; Xylinas E
World J Urol; 2021 May; 39(5):1357-1367. PubMed ID: 33128595
[TBL] [Abstract][Full Text] [Related]
18. Current State of Cell Therapies for Genitourinary Malignancies.
Alkhouli MA; Bazargan S; Pilon-Thomas S; Poch M; Chahoud J
Cancer J; 2022 Jul-Aug 01; 28(4):294-300. PubMed ID: 35880939
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers.
Labadie BW; Balar AV; Luke JJ
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771578
[TBL] [Abstract][Full Text] [Related]
20. Update on immunotherapy for renal cancer.
Canales Rojas R
Medwave; 2021 Jun; 21(5):e8202. PubMed ID: 34214067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]